| Market Capitalization (Millions $) |
62 |
| Shares
Outstanding (Millions) |
43 |
| Employees |
179 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-128 |
| Cash Flow (TTM) (Millions $) |
-19 |
| Capital Exp. (TTM) (Millions $) |
0 |
Repare Therapeutics Inc
Repare Therapeutics Inc. is a biotech company that focuses on the development of innovative precision cancer therapies using its proprietary SNIPRx platform. The company's platform uses synthetic lethality, a mechanism where targeting two genes would result in cell death, to identify novel and selective targets for the treatment of cancer.
Repare's technology works by screening synthetic lethality pairs in a large library of cancer cells to identify targets that are crucial for cancer cell survival. The company then develops small molecule drug candidates that selectively target these vulnerabilities without harming healthy cells.
Repare's pipeline includes four preclinical programs and one clinical program, RP-3500, which is a potential first-in-class oral small molecule targeted therapy that inhibits DNA-PK, a kinase that plays a critical role in DNA damage response and repair pathways that are essential for cancer cell survival. RP-3500 is currently being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors.
Additionally, Repare has collaborations with industry leaders like Bristol Myers Squibb and Vertex Pharmaceuticals to develop innovative cancer therapies using its SNIPRx platform.
Apart from its novel technology, Repare also has a robust intellectual property portfolio, comprising more than 50 patent applications with worldwide coverage.
The company's leadership team comprises world-renowned scientists with extensive experience in genomic medicine, synthetic lethality, and drug discovery, including CEO Lloyd M. Segal, Chief Medical Officer Dr. Steve Murray, and Chief Scientific Officer Dr. Michael Zinda.
Based in Montreal, Canada, Repare is backed by leading investors like Versant Ventures, MPM Capital, and Orbimed Advisors, among others. The company's vision is to become a leader in precision oncology by developing groundbreaking cancer treatments that help patients live longer and healthier lives.
Company Address: 7171 Frederick-Banting St-Laurent 0 QC
Company Phone Number: 412-7018 Stock Exchange / Ticker: NASDAQ RPTX
|
1.31% 